“High-Dose Pulse Therapy of Methylprednisolone Does Not Improve COVID-19 ARDS Outcomes and Increases Bacterial Pneumonia Risk: A Randomized Clinical Trial”

https://pubmed.ncbi.nlm.nih.gov/38116548

This randomized clinical trial found that using a high-dose pulse therapy of methylprednisolone in patients with mild to moderate ARDS due to COVID-19 did not improve in-hospital clinical outcomes and was associated with a higher risk of bacterial pneumonia.